Cellworks Group , a pioneer in Personalized Therapy Decision Support and Precision Drug Development, has unveiled groundbreaking findings from a real-world study on gastroesophageal cancer. The study showcased that Therapy Response Index (TRI) scores, generated through the Cellworks Biosimulation Platform, could predict overall survival (OS) beyond standard clinical factors such as age, sex, and TNM staging. Additionally, significant correlations were observed between a patient’s TRI score and disease-free survival (DFS) and tumor regression grade (TRG).
The peer-reviewed paper, titled ‘Integration of genomic aberrations to predict clinical outcomes for patients with gastroesophageal adenocarcinoma receiving neoadjuvant chemotherapy,’ is available at ESMO Gastrointestinal Oncology.
Despite advancements in gastroesophageal cancer therapy, long-term survival remains elusive for many patients. The study highlighted the limitations of previous precision-based approaches, emphasizing the need for a more comprehensive strategy. Dr. Elizabeth Smyth, Co-Principal Investigator of the study, stressed the potential of computational biomarkers in refining treatment selection for gastroesophageal patients, moving beyond specific biomarkers like HER2, MSI, PD-L1, and CLD18.2.
Dr. Rebecca Fitzgerald, Co-Principal Investigator, emphasized the challenge of translating complex genomic data into actionable clinical decisions and lauded the potential of whole genome sequencing combined with Cellworks’ biosimulation for optimizing treatment strategies.
Dr. Michael Castro, Chief Medical Officer at Cellworks, emphasized the transformative role of artificial intelligence (AI)-level molecular diagnosis in making genomic information actionable. He noted that Cellworks’ biosimulation makes the oncogene-only approach to precision medicine obsolete.
The clinical study involved 270 patients with gastroesophageal adenocarcinoma, utilizing 50x whole genome sequencing. Cellworks’ biosimulation, employing a Computational Biology Model (CBM), integrated genomic aberrations to predict therapeutic outcomes. Results indicated significant associations between TRI values and overall survival (OS), disease-free survival (DFS), and tumor regression grade (TRG). In conclusion, the study affirmed that TRI scores predict OS and DFS beyond standard clinical factors, highlighting the clinical value of Cellworks biosimulation for personalized therapy selection. Cellworks Group, Inc. leads in Personalized Therapy Decision Support and Precision Drug Development, utilizing a breakthrough CBM and biosimulation technology to improve patient outcomes.